Clinical Trials

Date: 2014-11-24

Type of information: Presentation of results at a congress

phase:

Announcement: presentation of results at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Francisco

Company: Cellectis (France)

Product: CART cell development programs including UCART19

Action mechanism: cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy

Disease:

Therapeutic area: Cancer - Oncology

Country:

Trial details:

Latest news:

• On November 24, 2014, Cellectis, a biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART), announced that three abstracts on the Company’s CAR-T cell development programs were accepted for presentation at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Francisco, December 6-9, 2014. The abstracts are listed below and available on the ASH conference website : “Multiplex Genome Editing As a Platform for “Off-the-Shelf” Adoptive CAR T-Cell Immunotherapies” (Abstract Number: 1111), “Allogeneic T-Cells Targeting CD123 for Adoptive Immunotherapy of Acute Myeloid Leukemia (AML)” (Abstract Number: 1116) and “In Vivo Proof of Concept of Activity and Safety of UCART19, an Allogeneic ‘Off-the-Shelf’ Adoptive T-Cell Immunotherapy against CD19+ B-Cell Leukemias” (Abstract Number: 4689).